General Information

1
H NMR spectra were recorded at 400 MHz with a Bruker Avance-400 or at 500 MHz with a Bruker DRX-500 spectrometer at 283 or 323 K. 13 C NMR spectra were recorded at 100 MHz with a Bruker Avance-400 and at 125 MHz with a Bruker DRX-500 instrument. Multiplicities are described using the following abbreviations: 
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Purification protocols and analytical data
Analytical data for proansamitocin (2) and derivatives 7-9a/b was reported before [S3] . Likewise, 20-chloro ansamitocin derivatives 11a-11e were described in [S4].
20-Chloro-proansamitocin derivatives 11f-h
Isolation of mutaproducts from large-scale fermentation was achieved by combining several fermentation broths, which were extracted with ethyl acetate, and the crude extract was subjected to a sequence of chromatographic purifications (Table S1 ). 
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The derivatives 11f (0.9 mg, 2.0 µmol, 1.0 mg/L), 11g (0.5 mg, 1.1 µmol, 0.5 mg/L) and 11h (1.8 mg, 3.7 µmol, 1.9 mg/L) were obtained as colorless solids. All fractions (11b-h) gave a total yield of 18.7 µmol, which corresponds to 1.6% with respect to aminobenzoic acid derivative 10 employed in the mutasynthetic experiment. (q, 14-Me), 11.4 (q, 4-Me) ppm, the quaternary atom C-18 could not be detected; Hz, 3H, 6-Me) ppm; All new metabolites listed in Table S2 and Table S3 were collected as colorless solids. By including the recovery of the starting compounds 9a and 9b overall 95% (9.2 µmol) and 77% (7.4 µmol) material, respectively, were (re)isolated. The derivatives 14 (23.7 mg, 44.3 µmol, 24 .7 mg/L), 15 (2.8 mg, 5.6 µmol, 2.9 mg/L) and 16 (0.7 mg, 1.6 µmol, 0.7 mg/L) were obtained as colorless solids following extraction and purification (Table S4) 
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